• About Us
  • Privacy Policy
  • Contact
Mortgage Insurance Center
  • Home
  • Mortgages
  • Health Insurance
  • Home Insurance
  • Life insuranace
  • Finance Laws
    • Banking Laws
    • Assets
    • Interest Rate
    • Loans
No Result
View All Result
  • Home
  • Mortgages
  • Health Insurance
  • Home Insurance
  • Life insuranace
  • Finance Laws
    • Banking Laws
    • Assets
    • Interest Rate
    • Loans
No Result
View All Result
Mortgage Insurance Center
No Result
View All Result
Home Assets

Successful Completion of Phase I Study for Lead Asset EP395

by Staff
May 18, 2022
in Assets
0
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

[ad_1]

EpiEndo logo

  • First non-antibiotic macrolide to go into clinical development – targeting COPD
  • Safety, tolerability and pharmacokinetic endpoints met
  • Phase II planning underway

REYKJAVIK, Iceland, May 18, 2022 / B3C newswire / — EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

EP395 is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’ to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD). EpiEndo is taking a novel approach to drug development for chronic respiratory diseases, focusing on enhancing the integrity of the epithelial cell layer in the lung to reduce disease-causing inflammation.

The study’s Principal Investigator was Professor Dave Singh, professor of clinical pharmacology and respiratory medicine at the University of Manchester. It was designed to assess the safety and tolerability of ascending single and multiple (up to 28 days) doses of the Barriolide™ EP395, administered as oral capsules in healthy subjects. EP395 was well tolerated and with pharmacokinetics consistent with once daily dosing. For more information on the study, see ClinicalTrials.gov.

Commenting on the study results, EpiEndo’s Chief Medical Officer, Ginny Norris, said: “The successful completion of this study brings us a step closer to addressing the global burden of COPD and other airway diseases by restoring and preserving epithelial integrity and reducing inflammation without the issue of potential anti-microbial resistance. We are now planning the next stage of clinical development for EP395 and look forward to initiating 2 clinical studies later this year including the first study with EP395 in COPD patients.”

Principal Investigator, Prof Dave Singh, added: “This First Time in Human study provides key clinical insights which highlight the potential for this new class of therapeutic – an encouraging step towards a new treatment for COPD.”

EpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023. The Phase Ib study will be a proof of pharmacology study in healthy volunteers. The Phase IIa study will assess the safety and tolerability of EP395 in patients with COPD, as well as assessing biomarkers for anti-inflammatory efficacy.

 

About EpiEndo Pharmaceuticals
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases.
EpiEndo is developing a proprietary portfolio of non-antibiotic macrolide drugs called Barriolides, with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

 

Contacts

EpiEndo Pharmaceuticals
Maria Bech, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
+354 454 0090­­­

Instinctif Partners (media relations)
Rozi Morris / Katie Duffell
This email address is being protected from spambots. You need JavaScript enabled to view it.
+44 20 7457 2020

 

Keywords: Humans; Chronic Disease; Pulmonary Disease, Chronic Obstructive; Macrolides; Lung; Inflammation; Anti-Inflammatory Agents; Epithelium; Epithelial Cells; Biological Products; Drug Development; Clinical Trials, Phase I as Topic; Pharmaceutical Preparations; Iceland

 

Published by B3C newswire

[ad_2]

Source link

Previous Post

DWP releases new guidance which could help more people access loans worth up to £812 within 14 days

Next Post

New Information Technology Findings from Kyoto Pharmaceutical University Discussed [The Use of Topical Antibiotics Based On the National Database of Health Insurance Claims and Specific Health Checkups of Japan (Ndb) Open Data In 2017]: Information Technology – InsuranceNewsNet

Next Post

New Information Technology Findings from Kyoto Pharmaceutical University Discussed [The Use of Topical Antibiotics Based On the National Database of Health Insurance Claims and Specific Health Checkups of Japan (Ndb) Open Data In 2017]: Information Technology – InsuranceNewsNet

Popular Posts

Ajanta Pharma : Newspaper Advertisements
Life insuranace

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

by Staff
July 28, 2022
0

Close Provided by: TAIMING ASSURANCE BROKER CO.,LTD. SEQ_NO 4 Date of...

Read more

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

20% interest rate on credit cards! Here’s how to avoid paying those high rates :: WRAL.com

Sens. Murphy, Blumenthal, Colleagues Reintroduce the Behavioral Health Coverage Transparency Act – InsuranceNewsNet

$1 billion in loans still available for agricultural funding in Ohio

How Long Do Car Accidents Stay on Your Record?

Rocket Mortgage Classic Wagers: Pick To Finish Top-10

Load More

Popular Posts

The perks and pitfalls of adjustable-rate mortgages in 2022

by Staff
June 13, 2022
0

Ajanta Pharma : Newspaper Advertisements

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

by Staff
July 28, 2022
0

Propy introduces blockchain title and escrow service

Propy introduces blockchain title and escrow service

by Staff
May 26, 2022
0

Ajanta Pharma : Newspaper Advertisements

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

July 28, 2022

20% interest rate on credit cards! Here’s how to avoid paying those high rates :: WRAL.com

July 28, 2022
Edelweiss General Insurance launches India’s first on-demand, mobile telematics-based comprehensive motor insurance – SWITCH

Sens. Murphy, Blumenthal, Colleagues Reintroduce the Behavioral Health Coverage Transparency Act – InsuranceNewsNet

July 28, 2022

Categories

  • Assets
  • Banking Laws
  • Finance Laws
  • Health Insurance
  • Home Insurance
  • Interest Rate
  • Life insuranace
  • Loans
  • Mortgages

Tags

home loans mortgage personal loan
  • Privacy Policy
  • contact us

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • About Us
  • contact us
  • Home
  • Home 2
  • Home 3
  • Privacy Policy

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.